Загрузка...
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
BACKGROUND: Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. METHODS: After stabilization on atorvastatin 10 mg, hypercholesterolemic subjects ≥65 years at high/very high risk for CHD and not at LDL-C <1.81 mmol/L (with atherosclerotic vascular...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3901347/ https://ncbi.nlm.nih.gov/pubmed/24411003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-511X-13-13 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|